KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Cash (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Change in Cash data on record, last reported at -$2.0 million in Q3 2025.

  • For Q3 2025, Change in Cash fell 190.18% year-over-year to -$2.0 million; the TTM value through Sep 2025 reached $10.9 million, up 131.38%, while the annual FY2024 figure was $9.0 million, 116.95% up from the prior year.
  • Change in Cash reached -$2.0 million in Q3 2025 per NKTR's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $42.8 million in Q1 2022 and bottomed at -$98.3 million in Q3 2021.
  • Average Change in Cash over 5 years is -$8.3 million, with a median of -$2.0 million recorded in 2025.
  • Peak YoY movement for Change in Cash: plummeted 4061.15% in 2021, then skyrocketed 337.96% in 2022.
  • A 5-year view of Change in Cash shows it stood at -$28.8 million in 2021, then soared by 39.13% to -$17.5 million in 2022, then tumbled by 69.09% to -$29.6 million in 2023, then skyrocketed by 147.71% to $14.1 million in 2024, then plummeted by 113.83% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$2.0 million in Q3 2025, $4.1 million in Q2 2025, and -$5.4 million in Q1 2025.